Genotoxic Impurities according to the Regulatory Perspective

[1]Patel Gargi, [2]Dr. Ronak Dedania,

[1]Research Scholar, [2] Professor & HOD, Pharmaceutics,
[1]Regulatory Affairs (Pharmaceutics),
[1] Bhagwan Mahavir College of Pharmacy, BMEF Campus, Nr. Akash E-Space, Bharthana, Vesu, Surat, Gujarat, India

***Abstract*—The area of pharmacy is concerned with using drugs in a smart and useful way to improve patient health. Pharmaceutical chemicals that have been developed will only help people's health if they are clean. Analytical chemistry is an important branch of science that lets us look at these flaws in both qualitative and quantitative ways. This improves the quality and safety of the end product. Recently, analytical chemistry has become an important part of the process of finding new drugs. There are many different ways to do both qualitative and quantitative research. These range from simple chemical tests to using the most advanced tools that are handled by software. As analysis science improves, we can lower the levels of discovery. This will help drug firms make sure that the drugs they sell are safe and of good quality. It is very important for pharmaceutical businesses to keep an eye on the quality of their raw materials, fillers, and produced goods.**

***Index Terms*—Genotoxic Impurity, Genotoxicity, Regulatory Perspective**

I. INTRODUCTION

Pharmaceutical analysis is an important part of getting drugs and their dose forms approved by government or the pharmaceutical business. For instance, quality assurance and quality control of medicinal dosage forms are needed to make sure that users can get dosage forms that are safe and efficient. Impurities can form in these medicines at different steps of production, shipping, and storage, and they need to be found and measured. The impurities are broken down into different groups, such as process-related impurities, breakdown products, enantiomers, genotoxic impurities, and so on. On a regular basis, new chemistry and physical methods are created that help figure out how pure drugs are and how many impurities they contain. There are a number of tools that can be used to test drugs, but HPLC is the most common. Along with drug purity analysis, the best thing about HPLC is that it can also be used to find small amounts of process-related impurities or stress-degrading impurities at the same time. A lot of attention has also been paid to using HPLC methods to figure out what drugs are because they are so useful for quality control. HPLC is a unique, flexible, and general tool that is widely used by researchers. It is easy to use, readily available, and can provide quality control of bulk drugs and their formulas.

Over the last 100 years, pharmacy and the pharmaceutical business have grown at an amazing rate, going from small shops and stores to global companies worth billions of dollars. Aside from the well-known R&D (research and development) of new medicinal goods, drug safety is becoming more and more important. In the last few decades, there have been a lot of problems in the pharmaceutical industry. These have included dangerous chemicals, wrong dose forms, drugs that were made stronger on purpose, and accidental contaminations. Today, making sure the patient is safe and comfortable is the most important part of healing sickness. To do this, you need high-quality medicines and treatments, as well as strict rules and methods for making them. It is impressive that health officials are trying to do things like this. For example, changing the name "GMP" (Good Manufacturing Practices) to "cGMP" (current) makes it clear that GMP compliance is a long-term goal [1]. Another example is the US Food and

Drug Administration (USFDA), which said in 2004 that it would switch from Quality by Test (QbT) to Quality by Design (QbD) [2]. This method was successfully accepted by the International Council for Harmonization (ICH), leading to the creation of several quality standards [3]. The main goal of QbD is to create large-scale production methods that allow for the creation of high-quality goods with little difference. When we talk about chemicals, a "impurity" is a material that is different from the chemicals that make up a defined chemical phase [4]. Having the quality of "purity" means that three main things must be true about a chemical compound [5]. Just to start, a pure chemical material needs to show up in at least one chemical phase and be able to be told apart from other chemicals by its one-component phase diagram. Second, a pure chemical must show that it is uniform in reality, which means that its qualities will not change after being put through a series of different diagnostic chemistry processes. In the perfect pure chemical, all studies and efforts to separate and clean it up even more will fail. Lastly, the usual description of a chemical says that it can't have any traces of any other chemical species. Really, there are no chemicals that are 100% pure because they are always contaminated in some way. In analytical chemistry [6], as detection limits go down, more contaminants are found.

Chemical synthesis considers flaws to be a bother, but they are usually not a big deal as long as it is clear what they are and how much there is. For as long as these chemicals do their job [7], chemists will accept molecules that are only 97.5% pure or even less. From the point of view of pharmaceuticals, this question is a lot trickier. In this case,

chemical synthesis doesn't just make a chemical substance; it also makes a substance

that is specifically meant to treat a medical problem. This is where impurities come in handy, since they can be given to patients along with the material that has them in it without meaning to. Genotoxic elements are those that directly damage DNA when they are present in small amounts, which can lead to changes and the chance of getting cancer [8]. PGIs, or possibly genotoxic impurities, are substances that show signs of being able to cause mutations. In reaction to the possible harm of PGIs, the government just recently put out a set of useful instructions [9].

GENOTOXICITY

Genotoxicity means that something damaging the genetic material (DNA and RNA) of a cell and affecting its stability. Genotoxins are radiation, chemical, or physical factors that change cells. Genotoxin is the name for a chemical that can damage DNA. Genotoxins

can be carcinogens, which are chemicals that cause cancer, mutagens, which are chemicals that cause mutations, or teratogens, which are chemicals that cause birth defects [10].

SOURCES

According to the Food and Drug Administration (FDA), the International Council for Harmonization (ICH), and the United States Pharmacopeia (USP), impurities can be broken down into four groups: heavy metals, leftover liquids, process-related impurities (PRIs), and drug-related impurities (DRIs). Impurities linked to active pharmaceutical ingredients (APIs) can be broken down into two groups. The first group is API impurities that happen because of processes, such as oxidation, dehydration, and carbon dioxide removal. The other kind is because of how the API interacts with the excipients, the container, or any pollutants that are still in the excipients, chemicals, or solvents. Because of how they interact with structure and function, API-related toxins may cause genotoxicity, mutation, and cancer [11]. Genotoxic impurities can be added from many places, mostly starting materials used to make drugs and their impurities in the form of genotoxic intermediates or process- related by-products during the making process. Moreover, manufacturing parts like solvents, catalysts, and reagents that are used to make drugs can also be genotoxic elements in drugs. Impurities are made in drug substances when they are stored, exposed to light, oxidized in the air, or broken down by water. When stereoselective drugs are made, they may contain stereoisomers of the raw materials and intermediates that help make chiral impurities in the drugs [12].

NEED OF GENOTOXICITY DETERMINATION

Before you begin to format your paper, first write and save the content as a separate text file. Genotoxicity data are used to figure out how dangerous drugs, food and feed, shopping goods, medicines for people and animals, and industry products are. Genotoxicity data are needed to figure out how dangerous natural environmental poisons are in food, feed, and drugs. Because of this, a lot of regulatory agencies and expert groups have given advice on how to test for genotoxicity. Even low amounts of exposure can have major effects on health when genetic materials are changed in cells like somatic and germ cells. Several inherited diseases are caused by changes in proto-oncogenes, tumor suppressor genes, or DNA damage response genes. These changes can be caused by physical or chemical agents. Somatic cells with broken DNA are also to blame for degenerative diseases like heart disease, stroke, immune system problems, and illnesses that damage nerve cells. An important part of chemical risk assessment is figuring out how likely it is that a chemical will cause mutations that could hurt people's health [13]. Regulatory bodies all over the world need regulatory data on the genotoxic potential of new drugs as proof that the product and process have been safely evaluated. Because of this, basic toxicity data of new chemical entities (NCE) are usually checked out in pre-clinical studies. Using toxicological data to figure out the safety and effectiveness of NCE will help in figuring out whether the drug is likely to have a risk or benefit assessment in the new drug application (NDA) process. It will also help in figuring out which chemicals are genotoxic and can damage DNA and make it harder to fix [14, 15].

II. TECHNIQUES TO DETECT GENOTOXIC IMPURITIES

To look at the impurities-sensitive, selective, and strong chemical methods that are needed to make control plans for GTIs that are reasonable and effective. The method chosen for testing GTIs is based on the goal specs and predicted numbers for these pollutants to meet legal requirements. Thus, the chosen method should produce reliable scientific data, and it should also be able to handle regular testing loads. Analytical methods are chosen based on how genotoxic they are and the chemical features of GTIs such as their different structures, how they respond to different detecting methods, and any possible matrix effects [16].

Analytical chemists face many problems when they try to figure out the ppm amount of GTIs in pharmaceuticals, such as

Choosing the right analytical technique for method creation based on a GTI's qualities, such as its volatility, heat stability, presence of a chromophore, hydrophobicity, and so on.

Things about GTI, like how quick it is and how stable the GI is, must be taken into account when the method is being developed to show proof of the needed accuracy and repeatability.

When developing a method, it is important to think about the practical amount, the length of the study, and the choice of a sensitive analysis method.

When making an analytical method, you need to think about things like which detecting method to use (ultraviolet [UV], light scattering, electrochemical detection, mass spectrometry, etc.). There are problems with the sample matrix that include matrix components that get in the way. These problems can be solved by: isolating the analyte of interest through sample preparation; using chromatographic resolution; or using a more selective detection.

A lot of different types of analysis can be used to look at GTI. It is hard to pick just one best method because they have so many different structures and the sample matrix is so complicated. But in an ideal world, there wouldn't be a single way to solve all problems. As time goes on, more and more people use traditional separations, hyphenated methods, and software-based in silico drug designs. Many labs in the pharmaceutical business use structured approaches to create GTI methods, which are made up of two steps:

Checking how volatile the element is to choose the right chromatographic methods For example, if the sample has a chromophore or a halogen atom in it, the detection method should be chosen based on those qualities.

CONVENTIONAL SEPARATION TECHNIQUES

High – Performance Liquid Chromatography (HPLC)

Through HPLC with UV detection, compounds that are not mobile and have aromatic or other molecular traits can be studied. The impurities and the API have structures that are very similar, which shows that the HPLC method is very selective and gives exact amounts. RP-HPLC, or reversed-phase HPCL, is also used a lot these days. Hydrophilic interaction LC (HILIC) can be used to get enough stability for analytes that are very polar. For GTIs that can only react in LC conditions or have a weak reaction to UV detection, chemical derivatization was needed to make the HPLC-UV method more sensitive. Different types of detectors, like evaporative light scattering detectors or charged aerosol detectors, can be used instead of UV detectors to improve the sensitivity and selection of low parts-per-million amounts of GTIs [17].

Chloramphenicol

The HPLC-UV derivatization method was used to find 4-nitrobenzaldehyde in injectable formulas using 2, 4-DNPH derivatization. The derivatization products salt- assisted liquid-liquid microextraction method was used for the extraction and concentrate. It also made the analysis more sensitive. The analysis was slowed down by the complexity of the concentrated derivatives and the low solubility of the analyte. As a result, 4-NBA in the drug was changed into 3-nitrophenylhydrazone. 3-normal pressure hydrocephalus hydrochloride (HCl), which was chosen because it was

sensitive, was used to remove GTIs and measure their amount [18].

HYPHONATAED TECHNIQUES

Gas chromatography-mass spectroscopy (GCMS)

GC/MS is a tool used to test complex organic and biological mixes. It is a combination of two instruments, GC and MS. GC is a very good way to sort chemicals that are volatile or semi-volatile. MS gives information about the structures of substances so that they can be precisely recognized and measured, but they can't be split up. Because of this, gas chromatography and mass spectrometry are often used together and work well with each other [19].

Valsartan

N-nitrosodimethylamine (NDMA) is a substance that is found in Valsartan pills. It is known that this material can cause cancer in humans, and it was added to the end product as a result of the production process. The GC/MS atmosphere method was thought to be able to find NDMA in Valsartan drug substances and drug goods. The Valsartan pills are taken off the market because they have a low limit of detection (LOD) of 0.05 and a low limit of measurement (LOQ) of 0.3 [20].

Divalproex sodium (DPS)

GC-EI-MS with SIM mode was used to measure and look at five genotoxic compounds in DPS drug material. They were methyl bromide (Me.-Br), ethyl bromide (Et.-Br), isopropyl bromide (Ipr.-Br), n-propyl bromide (n-Pr.-Br), and n-butyl bromide (n-But.-Br) [21].

Tolvaptan

During the final production process of tolvaptan, ethyl 4-bromobutyrate is used as a raw material. Based on its structure as primary alkyl halides, it was said to be a toxin that could cause cancer. From a legal and ICH point of view, this means that it must be shown that the amounts of ethyl 4-bromobutyrate were less than 1.5 µg/day based on the drug's maximum daily dose (MDD). Following the TTC method of the ICH standard, the maximum for ethyl 4-bromobutyrate possibly genotoxic impurities is set at 25 ppm. This is based on the MDD, which is 60 mg/day of tolvaptan [22].

LC-MS

LC-MS can be used in many ways to figure out the structure of impurities. It separates quickly and effectively, and the mass separation from the drug in the form of broken ions helps characterize and figure out the structure of impurities that aren't known. The mass-to-charge ratio gives you an idea of how molecules are put together. As LC-MS is very sensitive, it can find impurities in large samples at the femtogram level (1fg=10−gi g). The LC-MS data on molecular analysis shows the path that leads to an increase in impurities, which will help limit the amount of impurities in the drug product. LC-MS/MS was used in the study to find genotoxic impurities at very low amounts, lower the cost per analysis, get data quickly, and have an extremely low limit of measurement [28]

ADVANCED SOFTWARE BASED DRUG DESIGN

A few decades ago, scientists could guess whether drugs or chemicals would cause mutations by looking at their chemical makeup and how they might respond with DNA. There are two kinds of in silico systems: those that use substructures that are known to interact with DNA and those that use fragment-based quantitative structure activity relationship paradigms based on experimental data sets, such as the Ames test results. In silico systems speed up drug discovery and provide safety measures for workers in industry. They can also be used for in-house risk assessments of possible GTIs genotoxicity testing, but they need to be interpreted and confirmed by a person with a lot of knowledge.

III. CONTROL STRATEGY FOR GTIS

As of now, we know enough about the product and the process to plan a control strategy that will guarantee that the quality of the product and the performance of the process are free of GTIs (ICH Q10). The following choices are part of a control strategy:

- Controls over the properties of materials, such as raw materials, starting materials, stages, chemicals, solvents, and main packing materials
- Conditions under which the facility and tools are used
- Controls that are built into the way the product is made
- Controls that happen during the process, such as in-process studies and process factors
- Keeps an eye on drug substances and products (for example, release testing) [28].

The written advice from the FDA was a lot like the policy from the EMEA. Two important exceptions are:

- The FDA includes carcinogenic substances (many carcinogens are not genotoxic);
- The FDA includes extra safety gaps for children.

IV. CONCLUSION

There are many regulations and methods used for determination of the GTIS. We have here mostly used selectively and qualified method for determination used is GCMS. Many drugs liks Ranitidine, Famotidine and others are tested using these methods.

V. ACKNOWLEDGMENT

Conflict of interest: Nil

REFERENCES

[1] US Food and Drug Administration, and US Food and Drug Administration. Current good manufacturing practice (CGMP) regulations.2020.

[2] Pharmaceutical Cgmps for the 21 St Century-“A Risk-Based Approach Final Report”, 2004.

[3] Sharma A, Kumar SK. “Review on identification and quantification of genotoxic impurities”. International journal of health sciences. 2022;6(S7):4043-65.

[4] Demir I. “How and why should we decolonize global health education and research?”. Annals of Global Health. 2022;88(1).

[5] Van Brakel J. "Philosophy of science and philosophy of chemistry". HYLE–international journal for philosophy of chemistry. 2014 Dec 1;20(1):11-57.

[6] Ahuja S, Alsante KM, editors. "Handbook of isolation and characterization of impurities in pharmaceuticals". Academic press; 2003 Jul 18.

[7] Abdin AY, Yeboah P, Jacob C. "Chemical impurities: an epistemological riddle with serious side effects". International Journal of Environmental Research and Public Health. 2020 Feb;17(3):1030.

[8] Bercu JP, Dobo KL, Gocke E, McGovern TJ. "Overview of genotoxic impurities in pharmaceutical development". International Journal of Toxicology. 2009 Nov;28(6):468-78.

[9] Guidance for Industry Genotoxic and Carcinogenic Impurities in "Drug Substances and Products: Recommended Approaches"," 2008, Accessed: Nov. 28, 2021. [Online]. Available: http://www.fda.gov/cder/guidance/index.htm.

[10] Savale SK. "Genotoxicity of drugs: Introduction, prediction and evaluation". Asian Journal of Biomaterial Research. 2018;4(6):1-29.

[11] Liu KT, Chen CH. "Determination of impurities in pharmaceuticals: why and how?". InQuality management and quality control-new trends and developments 2019 Jan 31 (pp. 1-17). London, UK: IntechOpen.

[12] Shaikh T. "Genotoxic Impurities and Its Risk Assessment in Drug Compounds".

[13] EFSA Scientific Committee. "Scientific opinion on genotoxicity testing strategies applicable to food and feed safety assessment". EFSA Journal. 2011 Sep;9(9):2379.

[14] Shah SU." Importance of Genotoxicity & S2A guidelines for genotoxicity testing for pharmaceuticals". IOSR Journal of Pharmacy and Biological Sciences. 2012;1(2):43-54.

[15] Guideline IH. "Impurities in new drug substances Q3A (R2)". InProceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland 2006 Oct 25 (Vol. 25).

[16] Pierson DA, Olsen BA, Robbins DK, DeVries KM, Varie DL. "Approaches to assessment, testing decisions, and analytical determination of genotoxic impurities in drug substances". Organic Process Research & Development. 2009 Mar 20;13(2):285-91.

[17] Helmy R, Strickfuss S, Al-Sayah M, Hamilton S, Bu X, Lee C, Wang T, Welch C. "Quantification of Genotoxic Impurities in Active Pharmaceutical Ingredients". Pharmaceutical Industry Practices on Genotoxic Impurities. 2015:293-315.

[18] Luo L, Gu C, Li M, Zheng X, Zheng F. "Determination of residual 4- nitrobenzaldehyde in chloramphenicol and its pharmaceutical formulation by HPLC with UV/Vis detection after derivatization with 3- nitrophenylhydrazine". Journal of pharmaceutical and biomedical analysis. 2018 Jul 15;156:307-12.

[19] Hussain SZ, Khushnuma Maqbool KM. "GC-MS: principle, technique and its application in food science". Parr MK, Joseph JF. "NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines". Journal of Pharmaceutical and Biomedical Analysis. 2019 Feb 5;164:536-49.

[20] Parr MK, Joseph JF. "NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines". Journal of Pharmaceutical and Biomedical Analysis. 2019 Feb 5;164:536-49.

[21] Division of Pharmaceutical Analysis, Center for Drug Evaluation and Research. "GC/MS Headspace Method for Detection of NDMA in Valsartan Drug Substance and Drug Products". United States: Division of Pharmaceutical Analysis, Center for Drug Evaluation and Research; 2019.

[22] Reddy SR, Reddy KH, Kumar MN, Reddy PM, Reddy JV, Sharma HK. " Avalidated GC-MS method for the determination of genotoxic impurities in divalproex sodium drug substance". J Chromatogr Sci 2018;57:101-7.

[23] D'Souza AJ,Lokhande SR, Anvekar T. "Development and validation of GCMS method for the detection and quantification of potential genotoxic impurity ethyl 4-bromobutyrate in tolvaptan tablets". Int J Res Appl Sci Eng Technol 2018;6:2460-5.

[24] Zate PB, Kothari S, Lokhande MV. "Confirmation and quantification of genotoxic impurity 2-dimethylaminoethyl chloride hydrochloride (DMC HCl) by GCMS in chlorpheniramine/chlorphenamine maleate". J Appl Chem 2017;10:21-6.

[25] Maddala VL, Ray PC, Rao KN. "A sensitive and selective GC-MS method for analysis of genotoxic impurities in dobutamine hydrochloride". Orient J Chem 2016;32:1685-90.

[26] Gooty AR, Katreddi HR, Hunnur RK, Sharma HK, Masani NK. " Simultaneous determination of genotoxic impurities in fudosteine drugs by GC-MS". J Chromatogr Sci 2016;54:1277-81.

[27] Kakasaheb NA, Ramakrishna K, Srinivasarao V. "Method development and validation by GC-MS for quantification of 1-chloroethyl cyclohexyl carbonate as a genotoxic impurity in candesartan cilexetil drug substance". Int J Pharm Pharm Sci 2014;6:370-2.

[28] Akshatha HS, Gurupadayya BM. "Application of liquid chromatography coupled with mass spectrometry in the impurity profiling of drug substances and products". Asian J Pharm Clin Res 2018;11:30-7.